The earnings call presented a mixed picture with significant advancements in clinical trials and revenue growth, but also highlighted challenges such as reduced revenue per kit and increased operating expenses impacting profitability.
Company Guidance
During the Delcath Systems Third Quarter 2025 Earnings Conference Call, the company provided guidance on future site activations, financial projections, and clinical trial progress. Delcath expects to increase the number of active treating centers from the current 25 to 26-28 by the end of 2025, and further to 40 by the end of 2026. Revenue from HEPZATO reached $19.3 million in Q3 2025, with projected gross margins between 85% and 87% for the year. The company also adjusted its 2025 annual revenue guidance to $83-85 million. Delcath highlighted the positive results of the CHOPIN trial, demonstrating a 1-year progression-free survival (PFS) rate of 54.7% in the combination group versus 15.8% in the perfusion group, with statistically significant improvements in median overall survival and best overall response rate. The company plans to expand its sales force from 4 to 6 regions in 2025, and further to 9 regions by Q2 2026, to support site activation and build referral networks. Additionally, Delcath is conducting trials for liver-dominant metastatic colorectal and breast cancers, with interim data expected by 2027 and primary endpoint results in 2028 and 2029, respectively.
Increased Revenue from HEPZATO
Revenue from HEPZATO sales increased to $19.3 million in Q3 2025 compared to $10 million in the same period in 2024.
Positive CHOPIN Trial Results
CHOPIN trial showed significant improvements in the primary endpoint with 1-year PFS at 54.7% in the combination group versus 15.8% in the perfusion group.
Expansion of Treatment Sites
25 REMS-certified treatment sites with plans to expand to 40 by the end of 2026.
High Gross Margins
The company recognized gross margins of 87% in Q3 2025 compared to 85% in the same period last year.
Strong Cash Position
Ended the quarter with approximately $89 million in cash and investments and positive operating cash flow of $4.8 million.
Delcath Systems (DCTH) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DCTH Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 04, 2025
$9.52
$9.08
-4.62%
Aug 06, 2025
$10.52
$10.64
+1.14%
May 08, 2025
$11.61
$14.36
+23.69%
Mar 06, 2025
$13.43
$13.22
-1.56%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Delcath Systems (DCTH) report earnings?
Delcath Systems (DCTH) is schdueled to report earning on Mar 31, 2026, TBA (Confirmed).
What is Delcath Systems (DCTH) earnings time?
Delcath Systems (DCTH) earnings time is at Mar 31, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.